EyeGate opens doors to interested partner, buyer
This article was originally published in Clinica
Ophthalmic drug delivery specialist EyeGate Pharma reported that EGP-437 (dexamethasone) administered via iontophoresis achieved the same response rate as the standard of care for patients with anterior uveitis in a Phase III clinical trial.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.